Lixte Accounts Payable from 2010 to 2025
LIXT Stock | USD 1.28 0.06 4.48% |
Accounts Payable | First Reported 2006-03-31 | Previous Quarter 131.4 K | Current Value 72.9 K | Quarterly Volatility 90 K |
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Other Operating Expenses of 2.7 M, Total Operating Expenses of 2.7 M or Depreciation And Amortization of 6.1 M, as well as many indicators such as Price To Sales Ratio of 56.09, Dividend Yield of 2.0E-4 or PTB Ratio of 5.8. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
Lixte | Accounts Payable |
Latest Lixte Biotechnology's Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Lixte Biotechnology Holdings over the last few years. An accounting item on the balance sheet that represents Lixte Biotechnology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lixte Biotechnology are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Lixte Biotechnology's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable | 10 Years Trend |
|
Accounts Payable |
Timeline |
Lixte Accounts Payable Regression Statistics
Arithmetic Mean | 165,488 | |
Geometric Mean | 149,901 | |
Coefficient Of Variation | 38.92 | |
Mean Deviation | 45,302 | |
Median | 169,439 | |
Standard Deviation | 64,415 | |
Sample Variance | 4.1B | |
Range | 280.2K | |
R-Value | 0.51 | |
Mean Square Error | 3.3B | |
R-Squared | 0.26 | |
Significance | 0.04 | |
Slope | 6,879 | |
Total Sum of Squares | 62.2B |
Lixte Accounts Payable History
About Lixte Biotechnology Financial Statements
Lixte Biotechnology shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Lixte Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Lixte Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lixte Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Accounts Payable | 180.3 K | 169.4 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.